Karen Huebscher

Swiss / British

Chief Executive Officer of Solvias


Karen Huebscher is a Swiss/British citizen, Chairwoman of the audit committee, Tecan Group Ltd, CEO of Solvias AG and Founder and Managing Director of FibulaMedica AG. Karen is an accomplished Board‐level executive with a strong record in the Life Sciences industries.

She has served as CEO of Solvias since 2014. Solvias is a service provider to the Pharmaceutical, Biotech, Generics, Medtech and Cosmetics industries. As CEO of Solvias, managed the turnaround and transformation of the privately held company from 2014 until 2020, achieving a CAGR of 12% in revenue growth and triple-digit EBITDA expansion. In February 2020, the company signed a share purchase agreement with two PE investor groups, Water Street
Healthcare and JLL Partners. The deal was closed after achieving all required closing conditions despite the Coronavirus pandemic. Karen remains a significant shareholder in the company.

Karen has also founded and led FibulaMedical AG, a Switzerland‐based developer of MedTech products known for its US patents for a signature surgical bone drill in 2012. Karen’s company also provides consulting to large players in the pharmaceutical industry including AstraZeneca, Boeringher Ingelheim, etc.

Prior to creating FibulaMedical, Karen spent 15+ years at Novartis AG where she held Global top 400 positions in the Group such as Global Head of Investor Relations, Member of divisional Executive Committee and Innovation Board for Vaccines and Diagnostics.

In addition to her executive track‐record, Karen is a committed champion of Swiss excellence in Life Sciences Management: she currently sits on the Board of Tecan Group, a global leader in Life sciences robotics and diagnostics listed in Zurich, and on the Board of SMG, the Swiss Management Association.

As IMD EMBA alumni, Karen also holds a Master’s Degree in Animal Sciences and a PhD in Natural Sciences, both from ETH Zurich.